Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc. Common Stock（BCAX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · BCAX · 截至 2026年6月8日
活动摘要
买入笔数
2
P-Purchase only
卖出笔数
55
近12个月
买卖比
0.04
Buy/Sell (by trades)
整体情绪
Bicara Therapeutics Inc. Common Stock内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
BCAX 季度内部人买卖趋势
BCAX 内幕交易卖出 · BCAX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · BCAX CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
BCAX 高管卖出股份 · BCAX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 21, 2026 | Hyep Ivan CFO | Option | 9,200 | $35K | Form 4 |
| May 21, 2026 | Hyep Ivan CFO | Sale | 9,200 | $188K | Form 4 |
| May 18, 2026 | Mazumdar Claire CEO · Director | Option | 15,000 | $57K | Form 4 |
| May 18, 2026 | Mazumdar Claire CEO · Director | Sale | 12,022 | $240K | Form 4 |
| May 18, 2026 | Mazumdar Claire CEO · Director | Sale | 2,978 | $61K | Form 4 |
| May 15, 2026 | Cohlhepp Ryan President and COO · Director | Option | 8,000 | $30K | Form 4 |
| May 15, 2026 | Cohlhepp Ryan President and COO · Director | Sale | 8,000 | $162K | Form 4 |
| May 15, 2026 | Cohlhepp Ryan President and COO · Director | Sale | 4,500 | $91K | Form 4 |
| Apr 27, 2026 | Raben David Chief Medical Officer | Option | 5,500 | $21K | Form 4 |
| Apr 27, 2026 | Raben David Chief Medical Officer | Sale | 5,500 | $126K | Form 4 |
| Apr 21, 2026 | Hyep Ivan CFO | Option | 9,200 | $35K | Form 4 |
| Apr 21, 2026 | Hyep Ivan CFO | Sale | 9,200 | $212K | Form 4 |
| Apr 20, 2026 | Mazumdar Claire CEO · Director | Option | 15,000 | $57K | Form 4 |
| Apr 16, 2026 | Mazumdar Claire CEO · Director | Option | 7,080 | $39K | Form 4 |
| Apr 20, 2026 | Mazumdar Claire CEO · Director | Sale | 15,000 | $354K | Form 4 |
| Apr 16, 2026 | Mazumdar Claire CEO · Director | Option | 7,454 | $28K | Form 4 |
| Apr 16, 2026 | Mazumdar Claire CEO · Director | Option | 8,226 | $36K | Form 4 |
| Apr 15, 2026 | Cohlhepp Ryan President and COO · Director | Option | 8,000 | $30K | Form 4 |
| Apr 15, 2026 | Cohlhepp Ryan President and COO · Director | Sale | 8,000 | $184K | Form 4 |
| Apr 15, 2026 | Cohlhepp Ryan President and COO · Director | Sale | 4,500 | $104K | Form 4 |
| Mar 25, 2026 | Raben David Chief Medical Officer | Option | 5,500 | $21K | Form 4 |
| Mar 25, 2026 | Raben David Chief Medical Officer | Sale | 5,500 | $104K | Form 4 |
| Mar 23, 2026 | Hyep Ivan CFO | Option | 9,200 | $35K | Form 4 |
| Mar 23, 2026 | Hyep Ivan CFO | Sale | 9,200 | $170K | Form 4 |
| Mar 19, 2026 | Mazumdar Claire CEO · Director | Option | 6,905 | $26K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BCAX 内幕交易
BCAX 内幕交易
Bicara Therapeutics Inc. Common Stock（BCAX）内幕交易数据来源于公司内部人（包括Mazumdar Claire (CEO · Director), Cohlhepp Ryan (President and COO · Director), Hyep Ivan (CFO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。BCAX内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Bicara Therapeutics Inc. Common Stock机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
BCAX 内幕交易 · 5个问题Bicara Therapeutics Inc. Common Stock（BCAX）的内部人包括高管和董事，如Mazumdar Claire (CEO · Director), Cohlhepp Ryan (President and COO · Director), Hyep Ivan (CFO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026